Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

Brief description of study

chemotherapy. The goals of the study are to check how safe and well-tolerated both treatments are, how long people stay without their cancer getting worse, and how long the treatments help people improve. The study will also look at overall survival, how well the cancer responds to the treatment, and how long the positive effects last. Patients will be randomly assigned to either the combination treatment or olaparib alone after they’ve finished chemotherapy. The study will also collect tissue and blood samples for future research. This study is testing whether combining two treatments—one that damages cancer cells (olaparib) and one that boosts the immune system (pembrolizumab)—can help improve survival for people with this dangerous cancer.


Clinical Study Identifier: s24-01246
ClinicalTrials.gov Identifier: NCT04548752
Principal Investigator: Rafael Winograd.
Other Investigators: Daniel J Becker, Paul E. Oberstein, Kristen Spencer, Keriann M Scavone, Nina Beri, Jennifer Chuy, Shun Yu.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.